Data For Gilead’s Rising Hep C Star Sofosbuvir Support Initial Filing
This article was originally published in Pharmaceutical Approvals Monthly
Gilead reported results from three Phase III trials in February, with data strong enough to support U.S. and European filing for sofosbuvir, the nucleoside it plans eventually to make the foundation of a fixed-dose pill available by 2015.
You may also be interested in...
Much of the hep C wish list was on display at the American Association for the Study of Liver Disease meeting in Boston Nov. 10-13 – all-oral interferon-free drug combinations for hepatitis C, regimens that don’t require ribavirin, and the possibility of a one-pill, once-a-day cure – demonstrating the Gold Rush mentality in the hep C space as drug makers race to put the pieces together and grab a share of a burgeoning market.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.